Shares of Sequenom, Inc. (NASDAQ:SQNM) ended Tuesday session in red amid volatile trading. The shares closed down -0.03 points or -2.34% at $1.25 with 356,775.00 shares getting traded. Post opening the session at $1.26, the shares hit an intraday low of $1.23 and an intraday high of $1.30 and the price vacillated in this range throughout the day. The company has a market cap of $149.02 million and the numbers of outstanding shares have been calculated to be 119.22 million shares.
Sequenom, Inc. (SQNM) announced it will report financial results for the first quarter 2016 after closing of the NASDAQ Global Market on Wednesday, May 4, 2016.
A conference call hosted by Dr. Dirk van den Boom, President and CEO, and other members of senior management will take place on Wednesday, May 4, 2016, at 5:00 p.m. ET (2:00 p.m. PT) and will be webcast live on the Sequenom Website.
Call participants should dial 877-883-0383 (U.S. / Canada) or 412-902-6506 (other countries). Please use code 4043466. A telephonic replay will be available through June 3, 2016 by dialing 877-344-7529 (US toll free), 855-669-9658 (Canada toll free), or 412-317-0088 (international toll), and entering the conference number 10085264.
The conference call webcast is also accessible through the “Investors” section of the Sequenom Website at http://sequenom.investorroom.com/webcasts
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample. It also offers MaterniT21 GENOME test to detect genome-wide genomic deletions or duplications; HerediT cystic fibrosis (CF) LDT, a carrier screen test to identify individuals with CF or genetic mutations; and SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample. In addition, the company provides a microarray test that uses fetal samples obtained by amniocentesis or chorionic villus sampling under the NextView brand; and additional carrier screening tests for Ashkenazi Jewish disorders, spinal muscular atrophy, and fragile X syndrome under the HerediT brand. It serves physicians and client laboratories. The company has collaboration with the Recombine Inc. Sequenom, Inc. was founded in 1994 and is headquartered in San Diego, California.
For more info visit Website: http://www.sequenom.com